Life Sciences

  • March 26, 2026

    Regeneron Can't Sink Disability Bias Claims Over Scheduling

    A former Regeneron Pharmaceuticals director can proceed with her lawsuit claiming she was fired for requesting a flexible schedule to care for her daughter, a New York federal judge ruled, saying she'd sufficiently backed up allegations that doing so had violated federal disability bias law.

  • March 25, 2026

    PTAB Was Never '100% Discretionary,' Rep. Issa Tells Squires

    U.S. Patent and Trademark Office Director John Squires is exceeding the authority Congress intended to grant him in the America Invents Act for discretionarily denying patent challenges, the U.S. House of Representatives' intellectual property leader said Wednesday.

  • March 25, 2026

    AbbVie, Novartis Sue Wash. Over New 340B Drug-Pricing Law

    Pharmaceutical giants Novartis and AbbVie say a new Washington state law illegally expands drugmakers' obligations to provide deeply discounted medications under the federal government's 340B Drug Pricing Program, according to a pair of legal challenges launched in federal court on Wednesday.

  • March 25, 2026

    Ex-Pharma GC Freed From Trade Secrets Suit Amid Ch. 7 Stay

    A Texas federal judge agreed to dismiss claims against the ex-general counsel of a Houston-based pharmaceutical services company, who was accused of helping build a competing venture using confidential information and of destroying a hard drive containing evidence he had a duty to preserve during litigation.

  • March 25, 2026

    Co.'s Dual Citizenship Doesn't Kill Jurisdiction, 4th Circ. Told

    A medical supply company urged the Fourth Circuit on Wednesday to revive its suit against a U.K. company over COVID-19 test kits, arguing the Chinese citizenship of one of its members doesn't destroy a North Carolina federal judge's ability to hear the case.

  • March 25, 2026

    Mom Tying Abbott Formula To Baby's NEC Takes The Stand

    A plaintiff claiming Abbott Laboratories' preterm baby formula contributed to her infant's development of a serious gut condition told an Illinois jury Wednesday that she wouldn't have allowed her baby to consume the formula had she known it increased the risk of the infection, saying her now-teenage daughter still struggles with medical complications as a result.

  • March 25, 2026

    Fecal Treatment Co. Says Ch. 11 Is Best Option To Sell Assets

    Microbiome treatment developer Finch Therapeutics told a Delaware bankruptcy judge Wednesday that its lack of income or ability to collect on a patent judgment justified its Chapter 11 filing despite a lack of secured debts.

  • March 25, 2026

    Judge Trims SEC Fraud Case Over Cancer Drug Claims

    A Massachusetts federal judge greenlighted U.S. Securities and Exchange Commission claims against two of three former pharmaceutical executives accused of concealing from investors the U.S. Food and Drug Administration's "harsh critiques" about a cancer drug.

  • March 25, 2026

    Insurer Need Not Cover Parkinson's Drug Antitrust Dispute

    An insurer does not owe coverage in an antitrust suit accusing a pharmaceutical company of suppressing generic versions of the Parkinson's treatment Apokyn, a Maryland federal judge ruled, finding the dispute does not involve "securities claims" covered under the insurer's policy.

  • March 25, 2026

    Biotech 'Lowballed' Landlord On Lease Exit, Suit Says

    Biopharma company Werewolf Therapeutics has offered its Massachusetts landlord little more than 10 cents on the dollar to buy out the remainder of a lease for its lab space, even as the firm pays out departing executives and other creditors, according to a lawsuit brought in state court.

  • March 25, 2026

    Dechert Adds Paul Weiss Patent Partners In DC, NY

    Dechert LLP has hired two Paul Weiss Rifkind Wharton & Garrison LLP lawyers who have backgrounds in life sciences and electrical engineering, the firm announced Tuesday.

  • March 25, 2026

    Covington, Freshfields Advise On $6.7B Merck Oncology Deal

    Merck & Co. said Wednesday it will acquire clinical-stage oncology company Terns Pharmaceuticals Inc. for $53 per share in cash, giving the deal an equity value of $6.7 billion.

  • March 24, 2026

    Trump Admin Settles Suit Over Biden Social Media Collabs

    The Trump administration on Tuesday agreed to bar three federal agencies from interfering with social media companies' content moderation, resolving a high-profile challenge to the Biden administration's efforts to combat the spread of misinformation in a case that went up to the U.S. Supreme Court.

  • March 24, 2026

    Nicotine Pouch Maker To Refile FDA Suit In DC After Transfer

    The maker and seller of Zone nicotine pouches on Tuesday dismissed its own lawsuit accusing the U.S. Food and Drug Administration of unfairly holding up a market application for its product, promising to refile in D.C. federal court after a Texas federal court transferred it to South Carolina federal court.

  • March 24, 2026

    Agenus Escapes Investor Fraud Suit Over Cancer Drug

    A Massachusetts federal judge on Tuesday tossed securities fraud claims against Agenus Inc., saying the biotech company did not conceal the risk that a colorectal cancer therapy it was developing might face roadblocks.

  • March 24, 2026

    Drug Co. Atara Hit With Investor Suit Over FDA Denial

    Drug company Atara Biotherapeutics Inc. has been hit with a proposed class action accusing it of harming investors by not disclosing certain manufacturing problems and research study deficiencies that made it unlikely the U.S. Food and Drug Administration would approve its new drug application.

  • March 24, 2026

    Squires Institutes 6 Patent Reviews, Denies 15 Others

    U.S. Patent and Trademark Office Director John Squires has granted six petitions seeking America Invents Act reviews of patents and rejected 15 others, according to his latest summary order listing his most recent decisions.

  • March 24, 2026

    Sarepta Urges Full Fed. Circ. To Wipe Out Gene Therapy IP

    Sarepta Therapeutics Inc. wants the full Federal Circuit to rethink a decision reviving a University of Pennsylvania gene therapy patent, saying a panel got its analysis of patent eligibility wrong.

  • March 24, 2026

    ITC Says Hydrafacial Patent Infringed, But Won't Ban Imports

    The U.S. International Trade Commission has found that an aesthetics medical device company infringed a Hydrafacial LLC skin treatment patent, but stopped short of enforcing a ban on imports.

  • March 24, 2026

    CBP Frees Redesigned Smart Rings From Import Ban

    U.S. Customs and Border Protection has lifted an import ban issued by the U.S. International Trade Commission on smart rings made by Ultrahuman, finding that a redesign cleared the product of infringing a patent held by Ouraring.

  • March 24, 2026

    Fla. Judge Tosses Fired Reporter's Vaccine Suit Against PGA

    A Florida federal judge has ruled in favor of the PGA Tour in a lawsuit brought by a reporter who claimed she was fired for not complying with COVID-19 protocols, saying she couldn't claim a religious exemption. 

  • March 24, 2026

    FTC Rejects Bids To Block Gender-Affirming Care Probe

    A transgender medical care group and two healthcare trade organizations must turn over documents related to the group's claims made in their marketing and advertising for gender-affirming care for minors, the Federal Trade Commission ordered, denying the groups' motions to quash the agency's consumer protection investigation. 

  • March 24, 2026

    6 Firms Guide Gilead's $2.2B Autoimmune Drug Play

    Gilead Sciences Inc. has agreed to acquire privately held Ouro Medicines for up to $2.175 billion and is in advanced discussions with Galapagos NV on a potential research and development collaboration on the assets, according to an announcement late Monday from Gilead.

  • March 24, 2026

    Alston & Bird Hires Ex-FDA Deputy Counsel From DLA Piper

    Alston & Bird LLP announced on Tuesday it has hired a longtime government lawyer and former DLA Piper attorney to assist with the firm's work helping companies handle FDA compliance issues and regulatory disputes over medical products.

  • March 24, 2026

    FTC To Mull Caremark Deal In PBM Insulin Pricing Case

    Federal Trade Commission staffers have asked to let the agency's commissioners consider a potential settlement with Caremark in a case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes, following a recent deal with Express Scripts.

Expert Analysis

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • What Defense Teams Must Know About PFAS Testing Methods

    Author Photo

    Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.

  • Series

    Law School's Missed Lessons: Practical Problem Solving

    Author Photo

    Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.

  • Intellectual Property Challenges In AI-Driven Drug Discovery

    Author Photo

    Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.

  • Reel Justice: 'The Mastermind' And Juror Decision-Making

    Author Photo

    The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.

  • Learning From 2025 FCA Trends Targeting PE In Healthcare

    Author Photo

    False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.

  • Software Patents May Face New Eligibility Scrutiny

    Author Photo

    November guidance from the U.S. Patent and Trademark Office, along with recent litigation trends from the Federal Circuit, may encourage new challenges in the USPTO and district courts to artificial intelligence and software patents that rely on generic computing functions without concrete details, say attorneys at Venable.

  • Opinion

    A Uniform Federal Rule Would Curb Gen AI Missteps In Court

    Author Photo

    To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.

  • Riding The Changing Winds For AI Innovations At The USPTO

    Author Photo

    As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.

  • Series

    The Law Firm Merger Diaries: Integrating Practice Groups

    Author Photo

    Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.

  • Opinion

    Supreme Court Term Limits Would Carry Hidden Risk

    Author Photo

    While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Next Steps For Orgs. Amid Updated OpenAI Usage Policies

    Author Photo

    OpenAI's updates to its usage policies, clarifying that its tools are not substitutes for professional medical, legal or other regulated advice, sends a clear signal that organizations should mirror this clarity in their governance policies to mitigate compliance and liability exposure, say attorneys at Baker Donelson.

  • Series

    Knitting Makes Me A Better Lawyer

    Author Photo

    Stretching my skills as a knitter makes me a better antitrust attorney by challenging me to recalibrate after wrong turns, not rush outcomes, and trust that I can teach myself the skills to tackle new and difficult projects — even when I don’t have a pattern to work from, says Kara Kuritz at V&E.

  • How 11th Circ.'s Qui Tam Review Could Affect FCA Litigation

    Author Photo

    On Dec. 12, the Eleventh Circuit will hear arguments in U.S. ex rel. Zafirov v. Florida Medical Associates, setting the stage for a decision that could drastically reduce enforcement under the False Claims Act, and presenting an opportunity to seek U.S. Supreme Court review of the act's whistleblower provisions, say attorneys at Epstein Becker.

  • Series

    The Biz Court Digest: Welcome To Miami

    Author Photo

    After nearly 20 years in operation, the Miami Complex Business Litigation Division is a pioneer upon which other jurisdictions in the state have been modeled, adopting many innovations to keep its cases running more efficiently and staffing experienced judges who are accustomed to hearing business disputes, say attorneys at King & Spalding.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.